Maxygen Inc. was a biopharmaceutical company focused on developing improved versions of protein drugs using DNA shuffling and other protein modification technologies. The company was headquartered in Redwood City, CA. It dissolved in 2013. The Maxygen legacy was revived in 2018 with a focus on Directed Evolution of Proteins using Molecular Breeding. Maxygen LLC is currently headquartered in Sunnyvale, CA. Maxygen Inc's clinical programs included a novel G-CSF for the treatment of chemotherapy-induced neutropenia, which entered clinical trials in 2006. Maxygen also had a preclinical program, MAXY-4, to develop a novel CTLA4-Ig therapeutic for the treatment of rheumatoid arthritis and other autoimmune diseases. More information...
According to PR-model, maxygen.com is ranked 2,599,559th in multilingual Wikipedia, in particular this website is ranked 1,420,476th in English Wikipedia.
The website is placed before aks-corp.com and after steborice.cz in the BestRef global ranking of the most important sources of Wikipedia.
